Next Article in Journal
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
Previous Article in Journal
Pediatric Brain Tumours: Lessons from the Immune Microenvironment
 
 
Comment

Article Versions Notes

Curr. Oncol. 2023, 30(5), 5047-5049; https://doi.org/10.3390/curroncol30050380
Action Date Notes Link
article xml file uploaded 16 May 2023 05:45 CEST Original file -
article xml uploaded. 16 May 2023 05:45 CEST Update https://www.mdpi.com/1718-7729/30/5/380/xml
article pdf uploaded. 16 May 2023 05:45 CEST Version of Record https://www.mdpi.com/1718-7729/30/5/380/pdf
article html file updated 16 May 2023 05:47 CEST Original file -
article html file updated 16 May 2023 05:47 CEST Update -
article html file updated 16 May 2023 05:48 CEST Update https://www.mdpi.com/1718-7729/30/5/380/html
Back to TopTop